Table 4.
Baseline characteristics and change in AAD, DAD and PWV after 1 year treatment with RAAS inhibition in 25 subjects
| Baseline | Follow up | P value | |
|---|---|---|---|
| Age | 64.2 ± 11.8 | ||
| Male gender, N (%) | 22 (88%) | ||
| Body mass index, kg/m2 | 29.1 ± 3.4 | ||
| Duration of diabetes, years | 5.2 ± 4.5 | ||
| HbA1c, % | 7.6 ± 1.5 | ||
| HbA1c, mmol/mol | 60.1 ± 17.7 | ||
| Median HbA1c since diagnosis, mmol/mol | 63.4 ± 17.6 | ||
| Maximum HbA1c since diagnosis, mmol/mol | 86.6 ± 25.6 | ||
| 24 h systolic BP, mmHg | 136.7 ± 19.3 | 131.6 ± 20.9 | 0.12 |
| 24 h diastolic BP, mmHg | 72.9 ± 10.1 | 70.7 ± 11.1 | 0.07 |
| Total cholesterol, mmol/L | 4.1 ± 1.0 | ||
| Smoking, N (%) | 4 (16%) | ||
| Serum aldosterone, pmol/L | 337.0 ± 190.8 | 238.8 ± 138.2 | 0.11 |
| AAD (10−3 mmHg−1) | 1.51 ± 1.15 | 1.97 ± 1.07 | 0.007 |
| DAD (10−3 mmHg−1) | 1.98 ± 1.29 | 1.96 ± 1.10 | 0.92 |
| PWV (m/s) | 8.95 ± 2.60 | 8.33 ± 3.58 | 0.42 |
Significant associations in italics
Abbreviations as in Table 1